Correlation Between Biotron and ImmunoCellular Therapeutics
Can any of the company-specific risk be diversified away by investing in both Biotron and ImmunoCellular Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biotron and ImmunoCellular Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biotron Limited and ImmunoCellular Therapeutics, you can compare the effects of market volatilities on Biotron and ImmunoCellular Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biotron with a short position of ImmunoCellular Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biotron and ImmunoCellular Therapeutics.
Diversification Opportunities for Biotron and ImmunoCellular Therapeutics
0.78 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Biotron and ImmunoCellular is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Biotron Limited and ImmunoCellular Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ImmunoCellular Therapeutics and Biotron is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biotron Limited are associated (or correlated) with ImmunoCellular Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ImmunoCellular Therapeutics has no effect on the direction of Biotron i.e., Biotron and ImmunoCellular Therapeutics go up and down completely randomly.
Pair Corralation between Biotron and ImmunoCellular Therapeutics
If you would invest 1.11 in Biotron Limited on September 14, 2024 and sell it today you would lose (0.01) from holding Biotron Limited or give up 0.9% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 1.56% |
Values | Daily Returns |
Biotron Limited vs. ImmunoCellular Therapeutics
Performance |
Timeline |
Biotron Limited |
ImmunoCellular Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Biotron and ImmunoCellular Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Biotron and ImmunoCellular Therapeutics
The main advantage of trading using opposite Biotron and ImmunoCellular Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biotron position performs unexpectedly, ImmunoCellular Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoCellular Therapeutics will offset losses from the drop in ImmunoCellular Therapeutics' long position.Biotron vs. Sino Biopharmaceutical Ltd | Biotron vs. Defence Therapeutics | Biotron vs. Aileron Therapeutics | Biotron vs. Enlivex Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Complementary Tools
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
CEOs Directory Screen CEOs from public companies around the world |